SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micro Computer is actively trending following its strong Q2 FY2026 earnings beat and new strategic partnerships, including a modular AI data center deal with SK Telecom, which is driving community expectations for a major breakout despite ongoing market volatility and arguments about its perceived range-bound trading.

Marvell Technology, Inc. engages in the design, development, and sale of integrated circuits. Its products include data processing units, security solutions, automotive, coherent DSP, DCI optical modules, ethernet controllers, ethernet PHYs, ethernet switches, linear driver, PAM DSP, transimpedance amplifiers, fibre channel, HDD, SSD controller, storage accelerators, ASIC, and Marvell government solutions. It operates through the following geographical segments: United States, Singapore, Israel, India, China, and Others. The company was founded by Wei Li Dai and Pantas Sutardja in 1995 and is headquartered in Wilmington, DE.

Marvell Technology Inc

Marvell Technology is surging following strong quarterly results and a bullish outlook, largely driven by accelerating AI and data center demand. The community is actively discussing management's significantly raised fiscal 2027 revenue guidance, which forecasts sustained growth through 2028, and applauding strategic acquisitions designed to enhance its 'all-optical' data center solutions.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending as the Serum Institute of India received approval for Phase 3 trials of its COVID-Influenza combination vaccine using Novavax's Matrix-M adjuvant, fueling community optimism for its high-margin royalty model driven by new partnerships and strong financial performance, despite ongoing market manipulation concerns.

Sweetgreen, Inc. owns and operates a chain of salad restaurants. It offers drinks, sides, local bowls, salads, plates, and warm bowls. The company was founded by Nicolas Jammet, Jonathan Neman, and Nathaniel E. Ru in November 2006 and is headquartered in Los Angeles, CA.

Sweetgreen Inc - Ordinary Shares - Class A

Sweetgreen is actively discussed following its recent earnings, which showed a decline in sales but also highlighted strategic moves like new wraps and a substantial insider stock purchase by the CEO. This has created a strong community divide between those who believe it's an undervalued turnaround play and others who remain skeptical of its profitability and past aggressive expansion.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services such as lead generation and content for other financial services institutions. The company was founded in 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi Technologies is trending amid strong community debate regarding its potential S&P 500 inclusion, further fueled by a new Mastercard stablecoin payments partnership and CEO Anthony Noto's recent $1 million insider share purchase. The stock's resilience on broad market downturns, combined with improving fundamentals versus historic oversold technicals, is a key discussion point among investors.

Onyx is an infrastructure for a multi-asset, scalable, and cryptographically secure ledger. Onyx functions as a blockchain-based technology that enhances financial ecosystems by enabling a more efficient and interconnected economy, with a mission to develop cryptographic ledgers that optimize security, scalability, and usability. XCN is native to the Onyx XCN Ledger Blockchain as well as the Onyx Goliath Blockchain. XCN is also used as an ERC-20 token for Staking and Governance.

Onyxcoin

Onyxcoin ($XCN) is trending due to widespread anticipation surrounding its impending Goliath Mainnet launch, which the community believes will bring significant utility and a built-in token burn mechanism. This excitement is tempered by a vocal skeptical faction that warns of recurring pump-and-dump cycles and questions the project's transparency and long-term viability within the broader crypto market.

DocuSign, Inc. engages in the provision of cloud-based electronic signature solutions, which helps companies and individuals securely collect information, automate data workflows, and sign anything. The firm automates manual and paper-based processes allowing users to manage all aspects of documented business transactions including identity management, authentication, digital signature, forms and data collection, collaboration, workflow automation, and storage. Its products include eSignature, CLM, Gen for Salesforce, Document Generation, Standards-Based Signatures, Notary and Web Forms. The company was founded by Thomas H. Gonser and Court Lorenzini in 2003 and is headquartered in San Francisco, CA.

DocuSign Inc

DocuSign is currently under significant pressure and trending lower as multiple analyst downgrades, citing concerns over AI's potential to disrupt its core business model, fuel a polarized community debate about its long-term viability versus it being an oversold value play.

Zcash is a privacy-focused cryptocurrency that uses trustless zero-knowledge proofs to enable fully encrypted transactions while maintaining blockchain transparency and security. It was the first cryptocurrency to implement zero-knowledge encryption for private peer-to-peer payments, addressing the fundamental privacy gap in traditional cryptocurrencies that expose transaction details publicly.   With a fixed supply of 21 million ZEC and a halving schedule similar to Bitcoin, Zcash allows users to prove transactions are valid without revealing sensitive information like wallet balances, transaction amounts, or participant identities, making it suitable for everyday payments, long-term savings, and cross-border money transfers where financial confidentiality matters.  The protocol operates on its own blockchain currently using Proof-of-Work consensus, though it's evolving toward Proof-of-Stake through the planned "Crosslink" upgrade to enhance security, scalability, and energy efficiency. Zcash employs trustless zero-knowledge proofs (Halo) within its Orchard shielded pool to verify transactions without revealing sender, receiver, or amount information.   Users can choose between transparent public transactions and shielded private transactions through Unified Addresses, which work with both types. The network is faster and cheaper than Bitcoin, with new blocks mined every 75 seconds and transaction fees typically just a fraction of a cent. Privacy adoption has surged in 2025, with over 30% of total ZEC supply now held in fully shielded pools.  Zcash was created by a group of scientists in 2013 who initially proposed Zerocoin as a privacy extension to Bitcoin before building a standalone protocol. The ecosystem operates with a self-funded development model where block rewards support independent teams through the Zcash Community Grants Committee and a new Coinholder-Controlled Fund.

Zcash

Zcash is seeing significant community attention following the SEC's conclusion of its investigation into the Zcash Foundation without enforcement action and an upcoming Binance listing, with new Gemini support also adding to the buzz. Many are actively discussing its robust privacy features and anticipating a major rally as regulatory clarity for the crypto sector continues to develop.

Amprius Technologies, Inc. engages in the development, manufacture, and market lithium-ion batteries for mobility applications, including the aviation, electric vehicle and light electric vehicle industries. It operates through the United States and Rest of the World geographical segments. The company was founded by Mark C. Platshon in 2008 and headquartered in Fremont, CA.

Amprius Technologies Inc

Amprius Technologies Inc. is trending on strong earnings results that beat revenue estimates and provided robust 2026 guidance, showcasing significant growth in its high-energy silicon-anode batteries. The community is actively discussing its critical role in the accelerating defense and aerospace drone markets, where its NDAA-compliant production is a key advantage, positioning it as a potential momentum leader in national priority sectors.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Wedbush Cuts Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $29.00

Wedbush cut their target price on Sarepta Therapeutics from $34.00 to $29.00 and set an "outperform" rating on the stock in a report on Monday...

Sarepta Therapeutics (NASDAQ:SRPT) Earns Sell Rating from HC Wainwright

HC Wainwright reaffirmed a "sell" rating and issued a $5.00 target price on shares of Sarepta Therapeutics in a research note on Monday...

Sarepta Therapeutics, Inc. $SRPT Shares Purchased by Vanguard Group Inc.

Vanguard Group Inc. increased its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 18.1% in the 3rd quarter, according to its most recent disclosure with the SEC. The...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives Consensus Recommendation of "Hold" from Brokerages

Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Get Free Report) have been assigned a consensus rating of "Hold" from the twenty-eight ratings firms that are presently covering the firm...

Sarepta Therapeutics (NASDAQ:SRPT) Stock Rating Upgraded by Wall Street Zen

Wall Street Zen upgraded shares of Sarepta Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday...

Wells Fargo & Company Cuts Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $38.00

Wells Fargo & Company decreased their price objective on shares of Sarepta Therapeutics from $45.00 to $38.00 and set an "overweight" rating on the stock in a research report on Friday...

Sarepta Therapeutics Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)

Sarepta Therapeutics Announces Call for Applications for the 9th Annual Route 79, The Duchenne Scholarship Program

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the official opening of Route 79, The Duchenne Scholarship Program for the...

Erste Asset Management GmbH Has $50.59 Million Stock Position in Sarepta Therapeutics, Inc. $SRPT

Erste Asset Management GmbH boosted its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 65.7% in the 3rd quarter, according to its most recent filing with the...

Sarepta Therapeutics (NASDAQ:SRPT) Stock Price Down 9% Following Weak Earnings

Sarepta Therapeutics (NASDAQ:SRPT) Stock Price Down 9% Following Weak Earnings...

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Software / SaaS

Cybersecurity

Cloud Infrastructure

AI / Semiconductors

Which beaten-down sector are you buying first?

Stocktwits

Stocktwits Polls

Traders are actively watching for a potential short squeeze, citing high short interest and deep undervaluation compared to revenue and market cap.

High anticipation builds for upcoming Phase 1/2 data from the SRP-1003 (DM1) program, with expectations for strong knockdown and splicing correction data.

Intense debate surrounds key FDA officials Vinay Prasad and Makary, with users concerned about their regulatory influence impacting drug approvals and existing therapies.

Discussions focus on CEO Doug Ingram's passionate defense of the company, his leadership, and implications of his upcoming retirement amidst strong market skepticism.

Traders express deep frustration over the stock's inability to sustain gains or rise with the broader market, frequently dropping after minor upticks.

Fiscal Period	Estimated	Reported	Surprise	Result
Q1 '26	$1.14	--	--	N/A
Q4 '25	-$1.20	-$3.93	-228.26%	MISSED
Q3 '25	-$0.73	-$1.80	-147.60%	MISSED
Q2 '25	$0.83	$1.89	127.08%	BEAT
Q1 '25	-$3.21	-$4.60	-43.44%	MISSED

SRPT
Sarepta Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q4 '25

Historical Earnings

Latest SRPT News

SRPTSarepta Therapeutics Inc